selective oral serine protease FXia inhibitor

projected BID dosing in patients

from 1.8k cmpd protease inh. screen + SBDD

J. Med. Chem., Jun. 17, 2020

Novartis (NIBR), Basel, Switzerland

Structure of compound 23

“compound 23” is an oral, selective Factor XIa inhibitor intended as an anticoagulation agent. Since the clinical translatability of FXIa inhibition in preclinical models hasn’t been established, this program was…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: